Fusion Antibodies Plc (GB:FAB)
LSE:FAB
Top Page
Fusion Antibodies Plc
(LSE:FAB)
Select Model
Select Model
Rating:44Neutral
Price Target:
11.50 p
▼(-20.69% Downside)
Action:ReiteratedDate:12/20/25
Fusion Antibodies Plc's overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Outsourced CRO Business Model
Fusion operates a fee-for-service CRO model supplying antibody discovery and engineering to biotech, pharma and diagnostics. This model benefits from structural outsourcing trends, providing recurring project revenue, client diversification by therapeutic area, and relatively predictable demand for lab services over months.
Negative Factors
Severe Unprofitability
Extremely negative EBIT and net margins show the business currently loses large amounts on operations, meaning revenue growth alone may not be sufficient. Persistent deep losses erode capital, limit reinvestment, and require corrective cost or pricing changes to achieve sustainable profitability over the 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Outsourced CRO Business Model
Fusion operates a fee-for-service CRO model supplying antibody discovery and engineering to biotech, pharma and diagnostics. This model benefits from structural outsourcing trends, providing recurring project revenue, client diversification by therapeutic area, and relatively predictable demand for lab services over months.
Read all positive factors
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.94M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue Growth-11.43%
EPS Growth23.40%
CountryUK
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,021,880
10 Day Avg. Volume2,164,859
30 Day Avg. Volume1,162,225
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.81
Price to Sales (P/S)3.00
P/FCF Ratio-4.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fusion Antibodies Plc Business Overview & Revenue Model
Company Description
Fusion Antibodies Plc (FAB) is a biotechnology company specializing in the development and production of fully human monoclonal antibodies. The company operates primarily in the life sciences sector, providing a range of services including antibod...
How the Company Makes Money
Fusion Antibodies primarily makes money by selling fee-for-service R&D work to external customers (typically biotech, pharma, and diagnostics companies). Revenue is generated from contracted projects across antibody discovery and engineering workf...
Fusion Antibodies Plc Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60M | 1.97M | 1.14M | 2.90M | 4.80M | 4.17M |
| Gross Profit | 290.00K | 430.00K | -265.00K | 202.00K | 1.72M | 1.31M |
| EBITDA | -1.36M | -1.62M | -2.06M | -2.48M | -573.00K | -532.00K |
| Net Income | -1.47M | -1.71M | -2.23M | -2.60M | -1.20M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 1.81M | 1.32M | 2.42M | 2.06M | 4.92M | 5.83M |
| Cash, Cash Equivalents and Short-Term Investments | 252.00K | 359.00K | 1.20M | 195.00K | 2.05M | 2.69M |
| Total Debt | 671.00K | 20.00K | 43.00K | 75.00K | 69.00K | 230.00K |
| Total Liabilities | 1.09M | 654.00K | 627.00K | 939.00K | 1.23M | 1.08M |
| Stockholders Equity | 726.00K | 669.00K | 1.79M | 1.12M | 3.68M | 4.75M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -1.37M | -1.77M | -1.87M | -591.00K | -1.52M |
| Operating Cash Flow | -1.19M | -1.36M | -1.77M | -1.75M | -333.00K | -1.15M |
| Investing Cash Flow | -69.00K | -5.00K | 1.00K | -114.00K | -258.00K | -365.00K |
| Financing Cash Flow | 1.07M | 529.00K | 2.77M | 7.00K | -46.00K | 2.67M |
Fusion Antibodies Plc Technical Analysis
Positive
14.50
Price Trends
13.65
Negative
13.83
Negative
13.13
Negative
Market Momentum
-0.44
Negative
48.00
Neutral
72.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FAB, the sentiment is Positive. The current price of 14.5 is above the 20-day moving average (MA) of 12.74, above the 50-day MA of 13.65, and above the 200-day MA of 13.13, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 48.00 is Neutral, neither overbought nor oversold. The STOCH value of 72.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:FAB.
Fusion Antibodies Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £71.84M | 18.93 | 66.44% | 8.33% | -3.61% | -6.35% | |
56 Neutral | £119.34M | -4.45 | 90.29% | ― | ― | -94.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £9.37M | -1.89 | 377.33% | ― | ― | ― | |
44 Neutral | £15.94M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
42 Neutral | £285.19M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £16.18M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:FAB
Fusion Antibodies Plc
12.75
6.25
96.15%
GB:AVCT
Avacta Group plc
65.20
26.75
69.57%
GB:BVXP
Bioventix
1,375.00
-1,200.05
-46.60%
GB:SCLP
Scancell Holdings
11.50
3.60
45.57%
GB:GENF
Genflow Biosciences Plc
1.75
0.60
52.17%
GB:APTA
Aptamer Group Plc
0.60
0.33
122.22%
Fusion Antibodies Plc Corporate Events
Other
Fusion Antibodies Chair Adjusts Stake Through Family Share Transfer
Neutral
Feb 17, 2026
Fusion Antibodies plc, a specialist in therapeutic and diagnostic antibody discovery and engineering, has reported an internal share transfer involving its non-executive chair. The company operates integrated antibody development platforms such as...
Business Operations and Strategy
Rathbones Takes 7.74% Stake in Fusion Antibodies
Positive
Feb 4, 2026
Fusion Antibodies plc reported that Rathbones Investment Management Ltd, through Rathbones Nominees Limited, has built a holding of 9,679,837 ordinary shares in the company, equivalent to approximately 7.74% of its issued share capital. The increa...
Regulatory Filings and Compliance
Fusion Antibodies Confirms Total Voting Rights at 125 Million Shares
Neutral
Jan 30, 2026
Fusion Antibodies plc has confirmed that its issued share capital consists of 125,021,878 ordinary shares of 4 pence each, all carrying one voting right and with none held in treasury, establishing the total number of voting rights currently in th...
Business Operations and StrategyExecutive/Board Changes
Fusion Antibodies Pays Executive Bonuses in Shares as Part of Cost-Conscious Strategy
Neutral
Jan 27, 2026
Fusion Antibodies plc has issued 308,720 new ordinary shares to chief executive Adrian Kinkaid and chief scientific officer Richard Buick in lieu of a portion of their bonuses for the year to 31 March 2025, using the 13p issue price set in its rec...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Fusion Antibodies Raises £1.4m to Accelerate OptiMAL® Commercial Rollout
Positive
Jan 27, 2026
Fusion Antibodies plc has conditionally raised approximately £1.4 million before expenses via a non-pre-emptive placing and subscription of just over 11 million new ordinary shares at 13 pence, matching the previous day’s closing bid pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.